Overview
Key interactions: oral medications (delayed gastric emptying), insulin and sulfonylureas (hypoglycemia risk), oral contraceptives (PK considerations).
Related clinical pages
- STEP trial results
- SELECT trial results
- FLOW trial results
- Mechanism of action
- Dosing & pharmacology
- Contraindications
- Side effects
Key facts, checked November 20, 2026
The Wegovy label lists two interaction areas. First, semaglutide lowers blood sugar, so the risk of hypoglycemia rises with insulin or insulin secretagogues such as sulfonylureas, and the label suggests considering lower doses of those drugs when starting. Second, it delays gastric emptying, which can affect the absorption of oral medicines taken at the same time. Tell the prescriber about every medicine and supplement you take, and ask a pharmacist about timing. FDA’s November 9, 2026 safety communication adds a new class-wide eye warning to approved GLP-1 labels.